What exchanges is IMVT traded on?
IMVT is the stock ticker symbol for Immunovant, Inc., a clinical-stage immunology company focused on developing innovative treatments for autoimmune diseases. The company's common stock is officially listed and traded on the NASDAQ Stock Market, providing specialized biotech investors and institutional asset managers with liquid access to participate in its ongoing clinical advancements.
Related FAQs
Illinois Tool Works Inc. (ITW) is a Fortune 250 global multinational manufacturer of specialized industrial equipment, fasteners, consumables, and related component systems.
Equity research reports covering Immunovant generally assign favorable buy ratings, driven by its promising clinical-stage immunological pipeline targeting autoimmune diseases with novel antibody technologies.
Evaluating Immunovant as a long-term investment involves assessing its clinical-stage immunological pipeline targeting autoimmune diseases with novel monoclonal antibody therapies.
Immunovant is a clinical-stage immunology company focused on developing innovative, targeted antibody therapies for patients suffering from severe, IgG-mediated autoimmune diseases.
Immunovant, Inc. (IMVT) does not currently provide a dividend to its shareholders.
Market forecasts for Immunovant (IMVT) indicate a potential price target of approximately $39.39 by the end of 2026. Looking further into the future, long-term projections suggest the stock price may reach $22.66 by the end of 2029.